Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2018 /
Biomarkers of pembrolizumab response in head and neck cancer

14th - 18th Apr 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 4403

Dr Tanguy Seiwert - The University of Chicago Medicine, Chicago, USA

Dr Seiwert speaks with ecancer at AACR 2018 about potential biomarkers to predict patients with head and neck squamous cell carcinoma (HNSCC) responses to pembrolizumab.

He highlights markers derived from trial cohorts of over 200 patients, noting tumour mutational burden (TMB), PD-L1 expression and T-cell activated gene expression profile (GEP) as effective predictive markers for patients when use individually, or in combination.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation